News from thrombogenics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

10 Jul, 2017, 11:23 BST ThromboGenics and BioInvent Amending Long-standing Monoclonal Antibody Development Agreement

ThromboGenics NV (Euronext Brussels: THR) and BioInvent International AB ("BioInvent") (OMXS: BINV) today announce that they have agreed to amend...


08 Jun, 2017, 06:30 BST ThromboGenics to Present the Industry Pipeline of DME Treatments at Upcoming European Society of Ophthalmology Congress, Barcelona, Spain

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will ...


24 May, 2017, 06:30 BST ThromboGenics to present THR-317 Pre-clinical Research Findings at the European Association for the Study of Diabetes, Eye Complications Study Group (EASDec) Meeting in Budapest, Hungary

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that it will ...


11 May, 2017, 16:40 BST ThromboGenics Business Update - Q1 2017

Progressing Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio Highlights ThromboGenics continues to focus on progressing its...


02 May, 2017, 06:30 BST New ThromboGenics Ophthalmic Research Findings Presented at ARVO 2017 Annual Vision Research Meeting in Baltimore

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel treatments for diabetic eye disease, announced today that its...


20 Apr, 2017, 06:30 BST ThromboGenics Achieves Important Milestone in the Development of THR-149, A Novel Plasma Kallikrein Inhibitor for Diabetic Macular Edema

ThromboGenics, a biotechnology company focusing on novel treatments for back of the eye disease and diabetic eye disease, announced it has achieved...


16 Mar, 2017, 17:44 GMT ThromboGenics Business Update - FY 2016

- Innovative Diabetic Eye Disease Clinical and Pre-Clinical Portfolio - Provides "Multiple Shots on Goal" - First Patients Enrolled in Phase II...


10 Jan, 2017, 06:30 GMT ThromboGenics Enrolls First Patients in Phase II Clinical Study Evaluating THR-317 (Anti-PlGF) for Diabetic Macular Edema (DME)

THR-317 could become an attractive alternative or add-on treatment for current anti-VEGF medicines when treating DME or DR ThromboGenics NV (Euronext ...


20 Oct, 2016, 16:40 BST ThromboGenics Business Update - Q3 2016

- Diabetic Eye Disease clinical and pre-clinical programs on track - New Ophthalmic Research presented at EURETINA, EVER and AAO - Company Q3 2016...


11 Oct, 2016, 16:40 BST Latest ThromboGenics' Clinical Data to be Presented at 2016 American Academy of Ophthalmology (AAO) Meeting in Chicago

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, today announces that the...


07 Sep, 2016, 15:40 BST ThromboGenics Presenting New Ophthalmic Research Data

ThromboGenics NV (Euronext Brussels: THR), a Belgium-based biopharmaceutical company developing novel medicines for back of the eye disease, with a...


08 Aug, 2016, 06:30 BST ThromboGenics 2-Year OASIS Study Results Published in Ophthalmology, Journal of the American Academy of Ophthalmology (AAO)

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye diseases, today announces that the...


08 Jun, 2016, 16:40 BST ThromboGenics Receives US FDA Approval for New 'Already-Diluted' Formulation of JETREA®

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on developing novel medicines for back of the eye disease, today announces ...


13 May, 2016, 06:30 BST ThromboGenics Business Update - Q1 2016

Developing Novel Medicines Targeting Diabetic Eye Disease Highlights ThromboGenics is focused on developing novel medicines for the treatment of...


27 Apr, 2016, 07:00 BST New Ocriplasmin Research Findings Presented

New Data Confirm Appropriate Patient Selection Leads to Improved Treatment Outcomes, With no new Safety Signals Observed ThromboGenics NV (Euronext...


01 Mar, 2016, 07:00 GMT ThromboGenics to Host R&D Investor Meeting on Novel Disease-Modifying Approaches for Diabetic Eye Disease 18 March in London

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative treatments...


13 Jan, 2016, 06:30 GMT ThromboGenics Enrolls First Patient in Phase II CIRCLE Trial Evaluating Multiple Doses of Ocriplasmin to Induce a Total Posterior Vitreous Detachment in Patients With Non-Proliferative Diabetic Retinopathy (NPDR)

Assessing the potential of ocriplasmin to reduce risk of disease progression from NPDR to sight-threatening Proliferative Diabetic Retinopathy (PDR)...


04 Mar, 2014, 06:30 GMT ThromboGenics Initiates Major Post-Marketing Patient Trial with JETREA® in the US

Ocriplasmin Research to Better Inform Treatment (ORBIT) study designed to generate further data on the "real world" use of JETREA® ThromboGenics NV...


06 Dec, 2013, 23:03 GMT ThromboGenics' Founder Prof Desire Collen Retiring as Chairman

Dr Staf Van Reet appointed as new Chairman of the Board ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on ...


03 Dec, 2013, 06:30 GMT J-Code for ThromboGenics' JETREA to Become Effective January 1, 2014

Permanent J-Code J7316 will lead to streamlined reimbursement of JETREA® in the US ThromboGenics NV (Euronext Brussels: THR), an integrated...


22 Nov, 2013, 15:05 GMT ThromboGenics' Founder Prof Desire Collen Receives Scrip Lifetime Achievement Award

ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic...


20 Nov, 2013, 19:12 GMT ThromboGenics' Partner Alcon Launches JETREA® for the Treatment of Symptomatic Vitreomacular Adhesion in Canada

Canada is the first market launch for JETREA® outside the US and Europe ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical...


17 Oct, 2013, 20:01 BST Germany's G-BA Confirms That ThromboGenics' JETREA® Demonstrates Significant Therapeutic Benefits for Vitreomacular Traction (VMT) Patients, Including When Associated With Macular Hole

Decision confirms therapeutic benefits for treatment of VMT patients suffering from mild and moderate symptoms, or 94% of the indicated VMT...


01 Oct, 2013, 17:52 BST Euretina Presentation "Adoption of JETREA® in My Everyday Practice" Confirms Need for a New Paradigm in Treatment of Symptomatic VMA/ VMT, Including Those Cases Associated with MH

Largest ever retrospective review of VMA/VMT patients confirms early treatment initiation may stop disease progression and lead to better visual...


30 Sep, 2013, 06:30 BST ThromboGenics Establishes Level 1 ADR Program for US Investors

ThromboGenics NV (Euronext Brussels: THR:BR), a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines,...